Information Links
Previous Issues Volume 8, Issue 8 - 2023
Usefulness of Hebervital in the Treatment of Neutropenia in Patients with Oncopediatric Diseases
Caridad Verdecia Cañizares1,*, Regla Caridad Broche Candò2, Oramis Sosa Palacios3, Talia Marrero Amores4
1Oncology Department, University Pediatric Hospital, William Soler Ledea, Havana, Cuba
2Professor and Assistant Researcher in Neonatology, William Soler Ledea Pediatric University Hospital, Cuba
3Assistant professor in Biostatistics, Researcher Pediatric University Hospital, William Soler Ledea, Cuba
4Specialist in Pediatrics, William Soler Ledea Pediatric University Hospital, Cuba
*Corresponding Author: Dr. Caridad Verdecia Cañizares, Oncology Department, University Pediatric Hospital, William Soler Ledea, Havana, Cuba, Email: [email protected].
Received Date: July 20, 2023
Published Date: August 25, 2023
Citation: Cañizares CV, et al. (2023). Usefulness of Hebervital in the Treatment of Neutropenia in Patients with Oncopediatric Diseases. Mathews J Case Rep. 8(8):121.
Copyrights: Cañizares CV, et al. © (2023).
ABSTRACT
Introduction: cancer represents an important health problem in the world, the treatment for its cure leads to neutropenia with or without fever in most of these patients, requiring the use of Hebervital to achieve an increase in the percentage of neutrophils. Objective: To describe the clinical and epidemiological characteristics and the therapeutic results of Hebervital in oncopediatric patients with chemotherapy-induced neutropenia. Material and methods: a descriptive, cross-sectional and retrospective study was carried out from January 1, 2010 to December 31, 2022, in the Oncosurgery service of the William Soler Ledea Pediatric Hospital. The sample consisted of 415 treatment-induced neutropenia patients. Results: the male sex predominated in 62.4% of the patients. The most affected age range was from 5 to 9 and from 15 to 18 years. The tumors that most occurred: Non-Hodgkin lymphoma and Hodgkin's disease. Grade II and III neutropenia predominated. Neutrophil count normalized in 80% of cases within 72 hours of Hebervital treatment. Conclusions: the prevalence of chemotherapy-induced neutropenia is high, with predominance of males and between the ages of 5-9 and 15-18 years. The main localizations were non-Hodgkin's lymphoma and Hodgkin's disease. Moderate and severe neutropenia were more frequent, and the neutrophil count returned to normal, 72 hours after subcutaneous treatment with Hebervital.
Keywords: Effectiveness of Hebervital, Neutropenia, Paediatrics.
